SUDEEP PHARMA
|
SUDEEP PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 14.26 | 945.26 | 442.31 | 356.01 | 236.61 |
| CEPS(Rs) | 15.35 | 14.65 | 7.23 | 5.63 | 3.80 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 50.48 | 2,526.86 | 1,584.71 | 1,159.15 | 810.48 |
| Tax Rate(%) | 24.15 | 23.81 | 27.52 | 26.87 | 22.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 38.05 | 39.73 | 21.03 | 19.67 | 20.49 |
| EBIT Margin(%) | 37.80 | 39.09 | 21.40 | 20.50 | 20.45 |
| Pre Tax Margin(%) | 36.42 | 38.06 | 20.05 | 20.00 | 20.00 |
| PAT Margin (%) | 27.63 | 29.00 | 14.54 | 14.63 | 15.50 |
| Cash Profit Margin (%) | 29.74 | 30.96 | 16.38 | 15.95 | 17.14 |
| Performance Ratios | |||||
| ROA(%) | 22.54 | 28.54 | 16.33 | 18.03 | 19.41 |
| ROE(%) | 32.75 | 45.98 | 32.24 | 36.15 | 34.17 |
| ROCE(%) | 35.84 | 48.76 | 33.22 | 35.85 | 35.71 |
| Asset Turnover(x) | 0.82 | 0.98 | 1.12 | 1.23 | 1.25 |
| Sales/Fixed Asset(x) | 2.43 | 2.53 | 2.65 | 2.86 | 2.77 |
| Working Capital/Sales(x) | 2.01 | 3.32 | 7.24 | 6.91 | 10.92 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.41 | 0.40 | 0.38 | 0.35 | 0.36 |
| Receivable days | 119.94 | 94.68 | 85.40 | 86.25 | 72.54 |
| Inventory Days | 70.98 | 54.67 | 45.77 | 28.73 | 22.88 |
| Payable days | 133.44 | 100.79 | 68.31 | 63.28 | 59.30 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | - | - | - | - | - |
| Price/Book(x) | - | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.19 | 0.14 | 0.17 | 0.19 | 0.10 |
| EV/Core EBITDA(x) | 0.47 | 0.33 | 0.74 | 0.85 | 0.43 |
| EV/EBIT(x) | 0.50 | 0.35 | 0.80 | 0.90 | 0.47 |
| EV/CE(x) | 0.15 | 0.14 | 0.24 | 0.26 | 0.14 |
| M Cap / Sales | - | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.30 | 7.12 | 24.99 | 59.46 | 74.86 |
| Core EBITDA Growth(%) | 6.24 | 89.17 | 33.18 | 57.50 | 66.13 |
| EBIT Growth(%) | 5.68 | 95.67 | 30.49 | 59.86 | 72.30 |
| PAT Growth(%) | 4.13 | 113.71 | 24.23 | 50.46 | 84.83 |
| EPS Growth(%) | -98.49 | 113.71 | 24.24 | 50.46 | 84.83 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.27 | 0.21 | 0.37 | 0.51 | 0.27 |
| Current Ratio(x) | 2.43 | 2.01 | 1.35 | 1.34 | 1.25 |
| Quick Ratio(x) | 1.69 | 1.53 | 0.93 | 1.09 | 1.03 |
| Interest Cover(x) | 27.49 | 37.92 | 15.87 | 40.89 | 45.43 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of SUDEEP PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUDEEP PHARMA | ₹9,135.3 Cr | -4.2% | 16.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
SUDEEP PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUDEEP PHARMA | -4.2% |
16.3% |
|
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses
